Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,913 GBX | +3.18% | +6.34% | +6.93% |
Apr. 26 | HIKMA PHARMACEUTICALS : Hikma’s Q1 progress appreciated by the markets | |
Apr. 25 | Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024 | CI |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.93% | 5.29B | B+ | ||
+25.83% | 661B | C+ | ||
+27.00% | 566B | B | ||
-6.76% | 352B | C+ | ||
+20.34% | 332B | B- | ||
+3.00% | 283B | C+ | ||
+13.09% | 231B | B+ | ||
+5.46% | 200B | B- | ||
-9.61% | 195B | A+ | ||
-6.26% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HIK Stock
- Ratings Hikma Pharmaceuticals PLC